← Leaderboards
Benjamin Heath Durham
Sloan-Kettering Inst Can Research
$1,043,325
Attributed
$1,043,325
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $208.7K · FY2018–22$250K$187.5K$125K$62.5K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,043,325 · 1
By mechanism
K08$1,043,325 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Craig B Thompson$56,520,903
- James A Fagin$27,970,638
- Jason S Lewis$26,024,327
- Charles L Sawyers$34,701,646
- Milind Rajadhyaksha$15,078,152
Others in their field
Other Emerging Leaders on “Advisory Committees”
- Claudia Valmonte · The Emmes Company, Llc$37,865,589
- James Lu · Helix$12,461,593
- Hemali Phatnani · New York University School Of Medicine$12,067,974
- Patrick A Flume · Medical University Of South Carolina$11,656,627
- Sonia Savelli · University Of Washington$11,147,222
- Rajni Samavedam · Booz Allen Hamilton$9,935,296
Research focus
Advisory CommitteesAftercareBehaviorAffectBiological Response Modifier TherapyBraf GeneCancer CenterCareerBiologicalCellsClinical TrialsDerivation ProcedureDevelopmental BiologyDisease ModelDisease PhenotypeEffective TherapyEnvironmentEpithelialCd34 GeneEventExhibitsFacultyFrequenciesFunctional Genomics
Grant awards (5)
Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological Malignancies$208,665
K08 · FY2022 · CA · contact PI
Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological Malignancies$208,665
K08 · FY2021 · CA · contact PI
Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological Malignancies$208,665
K08 · FY2020 · CA · contact PI
Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological Malignancies$208,665
K08 · FY2019 · CA · contact PI
Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological Malignancies$208,665
K08 · FY2018 · CA · contact PI